Neonatal gram-negative infections, antibiotic susceptibility and clinical outcome: An observational study

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 101, Issue 6, 2016, Pages F507-F512

  Kent, Alison ^a   Kortsalioudaki, Christina ^a   Monahan, Irene M ^a   Bielicki, Julia ^a   Planche, Timothy D ^a,b   Heath, Paul T ^a   Sharland, Mike ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFEPIME; CEFOTAXIME; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BIRTH WEIGHT; CLINICAL OUTCOME; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN INFECTION; NEWBORN MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; URINARY TRACT INFECTION;

EID: 84995404842     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2015-309554     Document Type: Article

References (29)

1. Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004;292:2357-65.
2. Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126:443-56.
3. Vergnano S, Menson E, Kennea N, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011;96:F9-14.
4. Azizia M, Lloyd J, Allen M, et al. Immune status in very preterm neonates. Pediatrics 2012;129:e967-74.
5. Depani SJ, Ladhani SN, Heath PT, et al. The contribution of infections to neonatal deaths in England and Wales. Pediatr Infect Dis J 2011;30:345-7.
6. NICE guideline development group. Antibiotics for early onset neonatal infection. National Institute of Health and Clinical Excellence, 2012.
7. Turner MA, Lewis S, Hawcutt DB, et al. Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr 2009;9:50.
8. BNF for children. http://www.BNF.org (accessed 1 Jul 2015).
9. Metsvaht T, Nellis G, Varendi H, et al. High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination. BMC Pediatr 2015;15:41.
10. European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST Clinical Breakpoint guidelines website. http://www.eucast.org/clinical-breakpoints (accessed 8 Apr 2015).
11. Baş AY, Demirel N, Zenciroglu A, et al. Nosocomial blood stream infections in a neonatal intensive care unit in Ankara, Turkey. Turk J Pediatr 2010;52:464-70.
12. Srivastava R, Agarwal J, Srivastava S, et al. Multidrug resistant Gram-negative bacilli from neonatal septicaemia at a tertiary care centre in North India: a phenotypic and genotypic study. Indian J Med Microbiol 2014;32:97-8.
13. Tsai MH, Chu SM, Hsu JF, et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. Pediatrics 2014;133:e322-9.
14. Falagas ME, Tansarli GS, Rafailidis PI, et al. Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother 2012;56:4214-22.
15. Williams EJ, Embleton ND, Bythell M, et al. The changing profile of infant mortality from bacterial, viral and fungal infection over two decades. Acta Paediatr Int J Paediatr 2013;102:999-1004.
16. Isaacs D, Barfield C, Clothier T, et al. Late-onset infections of infants in neonatal units. J Paediatr Child Health 1996;32:158-61.
17. Gordon A, Isaacs D. Late onset neonatal Gram-negative bacillary infection in Australia and New Zealand: 1992-2002. Pediatr Infect Dis J 2006;25:25-9.
18. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91.
19. Bielicki JA, Lundin R, Sharland M. Antibiotic resistance prevalence in routine bloodstream isolates from children's hospitals varies substantially from adult surveillance data in Europe. Pediatr Infect Dis J 2015;34:734-41.
20. Lutsar I, Chazallon C, Carducci FIC, et al. Current management of late onset neonatal bacterial sepsis in five European countries. Eur J Pediatr 2014;173:997-1004.
21. Public Health England. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). Public Health England, London, UK, 2014.
22. McCormack JP, Jewesson PJ. A critical reevaluation of the 'therapeutic range' of aminoglycosides. Clin Infect Dis 1992;14:320-39.
23. Rao SC, Srinivasjois R, Hagan R, et al. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates (Review). Cochrane Database Syst Rev 2011;(11):CD005091.
24. Craig WA. The Postantibiotic effect. Clin Microbiol Newsl 1991;13:121-8.
25. Holmes NE, Johnson PDR, Howden BP. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol 2012;50:2548-52.
26. Hope R, Blackburn RM, Verlander NQ, et al. Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context. J Antimicrob Chemother 2013;68:2641-7.
27. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-20.
28. Esterly JS, Wagner J, McLaughlin MM, et al. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother 2012;56:4885-90.
29. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008;46:862-7.